Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 252
2021 247
2022 146
2023 98
2024 44
2025 29
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

718 results

Results by year

Citations

7 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. ...INTERPRETATION: In hospitalised COVID-19 pati …
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with …
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Rosas IO, et al. N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25. N Engl J Med. 2021. PMID: 33631066 Free PMC article. Clinical Trial.
METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) …
METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 …
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy.
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, Maiese A, Savioli G, Volonnino G, Longhitano Y. Zanza C, et al. Medicina (Kaunas). 2022 Jan 18;58(2):144. doi: 10.3390/medicina58020144. Medicina (Kaunas). 2022. PMID: 35208467 Free PMC article. Review.
Moreover, cytokine storm has recently emerged as a key aspect in the novel Coronavirus disease 2019, as affected patients show high levels of several key pro-inflammatory cytokines, such as IL-1, IL-2, IL-6, TNF-alpha, IFN-gamma, IP-10, GM-CSF, MCP-1, and IL-10, som …
Moreover, cytokine storm has recently emerged as a key aspect in the novel Coronavirus disease 2019, as affected patients show …
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Finkel D, Green A, Mallappallil M, Faugno AJ, Zhang J, Velez JCQ, Shaefi S, Parikh CR, Charytan DM, Athavale AM, Friedman AN, Redfern RE, Short SAP, Correa S, Pokharel KK, Admon AJ, Donnelly JP, Gershengorn HB, Douin DJ, Semler MW, Hernán MA, Leaf DE; STOP-COVID Investigators. Gupta S, et al. JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252. JAMA Intern Med. 2021. PMID: 33080002 Free PMC article.
IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release s …
IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) …
Therapeutic strategies for COVID-19: progress and lessons learned.
Li G, Hilgenfeld R, Whitley R, De Clercq E. Li G, et al. Nat Rev Drug Discov. 2023 Jun;22(6):449-475. doi: 10.1038/s41573-023-00672-y. Epub 2023 Apr 19. Nat Rev Drug Discov. 2023. PMID: 37076602 Free PMC article. Review.
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or …
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies th …
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Hermine O, et al. JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820. JAMA Intern Med. 2021. PMID: 33080017 Free PMC article. Clinical Trial.
IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). OBJECTIVE: To determine whether tocilizumab (TCZ) improves outcomes of patients hosp …
IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus …
Interleukin-6: obstacles to targeting a complex cytokine in critical illness.
McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. McElvaney OJ, et al. Lancet Respir Med. 2021 Jun;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872590 Free PMC article. Review.
Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cytokine as a therapeutic target. ...Here, we outline the role of IL-6 in health and disease, explain the different types of IL-6 signalling an …
Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cyt …
Repurposed Tocilizumab in Patients with Severe COVID-19.
Tian J, Zhang M, Jin M, Zhang F, Chu Q, Wang X, Chen C, Yue H, Zhang L, Du R, Zhao D, Zeng Z, Zhao Y, Liu K, Wang M, Hu K, Miao X, Zhang H. Tian J, et al. J Immunol. 2021 Feb 1;206(3):599-606. doi: 10.4049/jimmunol.2000981. Epub 2020 Dec 9. J Immunol. 2021. PMID: 33298617 Free PMC article.
In this study, we aimed to systematically describe the effectiveness of treatment and prevention of the cytokine storms in COVID-19 patients with tocilizumab. In this multicentered retrospective and observational cohort study, 65 patients with …
In this study, we aimed to systematically describe the effectiveness of treatment and prevention of the cytokine storms in COVID-1 …
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, De Peri E, Faletti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A, Modina D, Moioli G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E, Andreoli L, Latronico N. Toniati P, et al. Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3. Autoimmun Rev. 2020. PMID: 32376398 Free PMC article. Review.
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospita …
A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID …
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, Malakounidou E, Zarkadi E, Tsirikos G, Georgiopoulou V, Sotiropoulou V, Koulousousa E, Chourpiliadi C, Matsioulas A, Lagadinou M, Sampsonas F, Akinosoglou K, Marangos M, Tzouvelekis A. Karampitsakos T, et al. Clin Microbiol Infect. 2023 Mar;29(3):372-378. doi: 10.1016/j.cmi.2022.10.015. Epub 2022 Oct 20. Clin Microbiol Infect. 2023. PMID: 36273769 Free PMC article.
OBJECTIVE: Randomized controlled trials comparing tocilizumab and baricitinib in patients with coronavirus disease 2019 (COVID-19) are needed. ...DISCUSSION: In the setting of this trial, baricitinib was non-inferior to tocilizumab with r …
OBJECTIVE: Randomized controlled trials comparing tocilizumab and baricitinib in patients with coronavirus disease 2019 …
718 results